The FDA has approved Zoryve cream for the treatment of plaque psoriasis, Arcutis announced in a press release. A nonsteroid, phosphodiesterase-4 inhibitor, Zoryve (roflumilast cream 0.3%) is a once-daily topical treatment for psoriasis and the first PDE4 inhibitor approved for this indication.